For Immediate Release: November 18, 2015
Medpace adds medical leadership to support global drug development Dr. Glynis Neagle Joins Medpace as Vice President, Medical Affairs
CINCINNATI, OH — (November 18, 2015) – Glynis Neagle, MD has joined Medpace as Vice President, Medical Affairs to provide medical strategy and expertise for global clinical drug development. Dr. Neagle has over 20 years of experience in clinical trials. She has held senior level positions in medical affairs and clinical development for both pharmaceutical companies and Clinical Research Organizations (CROs) as well as being an investigator in clinical studies. Dr. Neagle most recently served as Chief Medical Officer.
Dr. Neagle’s clinical training is in Oncology and her global drug development experience aligns with Medpace’s expertise including oncology, metabolic/endocrine, cardiovascular, infectious disease, and gastroenterology. In addition, Dr. Neagle has experience in Phase IIIb and Phase IV post marketing studies. Dr. Neagle has participated on a variety of scientific advisory boards, chaired international meetings and provided expert opinion for drug development strategy. She received her BSc in Biochemistry and Immunology and her MB,Ch.B, Bachelor of Medicine and Surgery at the University of Glasgow in Scotland.
Dr. Neagle joins a growing team of medical doctors who support the company’s physician-led approach to clinical development. Medpace, a global drug development and medical device Clinical Research Organization (CRO), is unique in its physician-driven model which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Medpace medical doctors provide strategic direction for study design and planning, train operational staff, work with primary investigators, provide medical monitoring, and meet with regulatory agencies. This hands-on approach provides significant advantages that can shorten drug development timelines and reduce development risk.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace is unique in its physician-driven approach to clinical research which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Medpace has strong experience supporting development programs across a number of therapeutic and specialty areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, gastrointestinal diseases, regenerative medicine, pediatrics, and rare disease/orphan indications. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2300 employees and has clinical trial experience in over 45 countries and six regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and Africa. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.